

Phase III randomised double-blind placebo controlled study of rofecoxib (VIOXX) in colorectal cancer patients following potentially curable therapy

Submission date 01/07/2001	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 01/07/2001	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 11/08/2011	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof David J Kerr

Contact details
Department of Clinical Pharmacology
Old Road Campus Research Building
University of Oxford
Old Road Campus
Headington
Oxford
United Kingdom
OX3 7DQ

Additional identifiers

ClinicalTrials.gov (NCT)
NCT00031863

Protocol serial number
VICTOR

Study information

Scientific Title

Acronym

VICTOR - Vioxx In Colorectal cancer Therapy: definition of Optimal Regime

Study objectives

Added as of 24 January 2008:

1. Treatment with VIOXX® will result in improved overall survival compared with placebo
2. Treatment with VIOXX® will result in improved disease-free survival compared with placebo

Countries of recruitment amended as of 26 July 2007: Countries of recruitment provided at time of registration: International

Ethics approval required

Old ethics approval format

Ethics approval(s)

Added as of 26 July 2007: Approved by Clinical Trials Committee of the Cancer Research Campaign, the West Midlands Multicenter Research Ethics Committee, and local research ethics committees at participating centers.

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Colorectal cancer

Interventions

1. VIOXX: 25 mg once daily
2. Placebo: identical in appearance, once daily

As of 26 July 2007: Please note that this trial was terminated prematurely in September 2004 due to worldwide withdrawal of rofecoxib.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Vioxx (rofecoxib)

Primary outcome(s)

Added as of 24 January 2008:

Overall Survival

Key secondary outcome(s)

Added as of 24 January 2008:

1. Relapse-free survival
2. Thrombotic cardiovascular safety

Completion date

30/09/2004

Reason abandoned (if study stopped)

Vioxx withdrawn

Eligibility

Key inclusion criteria

1. Histologically proven Dukes Stage C (Stage III any T, N1-2, M0) or B (Stage II, T3 or 4, N0, M0) colorectal carcinoma
2. Complete resection of primary tumour without gross microscopic evidence of residual disease
3. World Health Organisation zero to one
4. Acceptable haematological and biochemical function
5. Within 12 weeks of finishing potentially curative therapy (Surgery +/- radiotherapy +/- chemotherapy)
6. Written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

Exclusion criteria added as of 26 July 2007:

1. Active peptic ulceration or gastrointestinal bleeding in the past year
2. History of adverse reactions to NSAIDs
3. Known sensitivity to rofecoxib
4. Those receiving long-term NSAID therapy (except for low-dose aspirin, =100 mg per day)
5. Younger than 18 years
6. Women who were pregnant, lactating, or premenopausal but not using contraception. 7.

History of cancer (other than adequately treated in situ carcinoma of the cervix or basal or squamous-cell carcinoma), inflammatory bowel disease, or severe congestive heart failure

Date of first enrolment

30/04/2002

Date of final enrolment

30/09/2004

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Department of Clinical Pharmacology

Oxford

United Kingdom

OX3 7DQ

Sponsor information

Organisation

University of Oxford (UK)

ROR

<https://ror.org/052gg0110>

Funder(s)

Funder type

Industry

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Funder Name

Merck and Co Inc

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	26/07/2007		Yes	No